ReviewChildren (Basel, Switzerland)2026

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months.

Andreea Văduva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.